Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results

Humacyte (NASDAQ:HUMA) released its quarterly earnings results on Friday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07, Zacks reports.

Humacyte Price Performance

NASDAQ HUMA opened at $1.96 on Friday. The company has a market cap of $246.68 million, a P/E ratio of -1.46 and a beta of 1.36. Humacyte has a 12 month low of $1.76 and a 12 month high of $9.97. The company has a 50-day moving average of $3.61 and a 200-day moving average of $4.50.

Analysts Set New Price Targets

Several equities analysts have weighed in on HUMA shares. Benchmark reissued a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Wednesday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.